NCT06357676 2026-01-30Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialOHSU Knight Cancer InstitutePhase 1/2 Recruiting27 enrolled
NCT05936229 2024-07-12Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyFred Hutchinson Cancer CenterPhase 1/2 Withdrawn